Novo Nordisk CEO Mike Doustdar has signaled the company is open to upgrading its listing in the United States. The Danish pharmaceutical group, best known for its obesity and diabetes drug Ozempic, is currently listed in Denmark. Doustdar stated he sees advantages in providing US investors with direct access to the stock.
The move would represent a shift from the current structure, where Novo Nordisk shares are available to American investors primarily through over-the-counter trading. An upgrade to a full US listing would typically involve listing on a major exchange, such as the NYSE or Nasdaq. This change would subject the company to stricter regulatory reporting requirements under US securities law. For a company of Novo Nordisk's size, the cost of compliance is a minor factor compared to the potential benefits of increased liquidity and investor base.
The primary driver, according to Doustdar, is direct access. Currently, US investors buy shares that are traded in Denmark, often with a time lag and without the full protection of US investor rights. A direct listing eliminates this friction. It allows US funds and individual investors to buy and sell shares in real-time during US market hours. This can lead to tighter bid-ask spreads and higher trading volumes. For a high-profile stock like Novo Nordisk, driven by the massive demand for GLP-1 drugs like Ozempic and Wegovy, liquidity is a key metric for institutional investors.
The decision is not immediate. Doustdar used the phrase "open to," indicating the company is evaluating the option rather than announcing a finalized plan. The board of directors would need to approve any such change. Factors to consider include the cost of dual reporting, the impact on Danish shareholders, and the potential dilution of voting power if new shares are issued. However, the strategic benefit of embedding the stock in the US market, where the majority of the demand for its products is generated, is significant.
The pharmaceutical sector has seen a trend of European companies seeking US listings to attract capital. Novo Nordisk is a standout case because its core product, Ozempic, is a US blockbuster. By aligning its equity listing with its primary revenue market, the company may aim to better reflect its value proposition to the global market. The move would also simplify the investment process for US-based asset managers who currently face hurdles in holding Danish equities directly.
No specific timeline or financial figures were provided regarding the potential upgrade. The statement serves as a signal of intent rather than a commitment. Investors will watch for further disclosures in upcoming earnings calls or regulatory filings. For now, the math of the decision rests on the balance between regulatory burden and market access. Doustdar's comment suggests the advantages of direct access outweigh the costs in the company's current assessment. The market will likely monitor this as a potential catalyst for the stock, given the increased visibility and liquidity it would bring.